Boyds makes a strategic move to Ireland to ensure continuity of service to clients after Brexit
L:R - Maria Johnston, Operations & Enterprise Development Manager, DCU Invent; Richard Stokes, Director of Innovation, DCU Invent; Siobhan Gaynor, Consultant of Business Development and Regulatory Affairs at Boyds, and Professor Alan Boyd, Boyds CEO
Boyds Consultants has announced the opening of an office in Dublin, Ireland. The move, the company said, will ensure the continuity of service to its clients once the UK leaves the EU on 29th March.
Professor Alan Boyd, founder and CEO, commented: “The UK’s departure from the EU has significant implications for the UK pharmaceutical industry. Both the European Commission and the European Medicines Agency have been very clear that for market authorisation holders to ensure their medicines can remain on the EU market, they have to be prepared for the UK to become a third country.”
Headquartered in Crewe, Cheshire (UK) Boyds' core business is to support the development of pharmaceutical and biotech products for patient benefit.
Established in 2015, Boyds has been in an expansion mode since last year, when the consultancy firm opened new premises outside Cambridge. The company now employs 20 members of staff.
Boyds said the Dublin office will provide the company with the foothold it needs in Europe to ensure clients can continue to benefit from access to the European Medicines Agency (EMA).
“The opening of our Dublin office is especially important to the work we do in supporting the development of medicines for patient benefit," Boyd said.
He added: “We work with clients across the globe who come to us for our regulatory expertise, and who wish to benefit from the easy access to the EMA that allows them to get development advice and gain market authorisation for their drugs and medical devices. We need to ensure we are positioned to continue this vital work with the EMA.”
As part of the move, Boyds has appointed Siobhan Gaynor to head up the office in Dublin as Consultant of Business Development and Regulatory Affairs.
Gaynor has over 28 years’ experience in a wide variety of research, business development and executive roles in clinical and translational health research across pharmaceutical companies, biotechnology start-ups and academia, including Spark Therapeutics, GlaxoSmithKline, Clinical Research Development Ireland and Cancer Trials Ireland.
Prior to joining Boyds, she worked as an R&D Advanced Therapeutics and Rare Disease specialist, providing consultancy services to clients in the area of gene therapy, technology transfer, portfolio prioritisation, programme management and company operations.
Commenting on her new role, Siobhan said: “I am delighted to be heading up Boyds’ new Dublin office. I have worked with Alan and his team in the past and was particularly impressed by their depth of experience and professionalism.
“I will bring my preclinical, clinical, regulatory and program management experience to Boyds, as well as my extensive knowledge of Irish companies.”
The new Irish branch will be based at DCU Invent on the Dublin City University Campus.
Richard Stokes, Invent CEO and DCU Director of Innovation, added: “We are very pleased that Boyds has chosen the DCU Invent as its new Dublin office.
“Our facility will enable Boyds to collaborate and forge strong links with researchers working in Dublin, helping the firm to innovate further and support its ongoing growth plans," he concluded.